Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of cardiac surgery-associated acute kidney injury
2021-004938-11Phase 4Active
- Sponsor
- Hospital Clínico Universitario de Valladolid
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin in acute kidney failure (AKF) and cardiac morbidity, sponsored by Hospital Clínico Universitario de Valladolid. Primary endpoints: Incidence of postoperative acute kidney injury (KDIGO stage 1 or higher) and Perioperative mortality. Started Oct 2021; status: active.
02
Drugs
empagliflozin
03
Conditions
acute kidney failure (AKF)cardiac morbidity
Beyond the preview
Go deeper on 2021-004938-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004938-11.